Combination of Niraparib and Anlotinib in Patients with Recurrent or Metastatic Endometrial Cancer: An Open-Label, Single-Arm, Two-Stage, Phase II Study
To evaluate the efficacy, safety, and potential predictive biomarkers of the combination of the PARP inhibitor niraparib and the antiangiogenic anlotinib in patients with recurrent or metastatic endometrial cancer (r/mEC) who have received at least one prior line of systemic therapy. To further explore the mechanism of anlotinib combined with niraparib in the treatment of EC, ishikawa cells were treated with the drugs and then analyzed using RNA-seq.